An Alexion Pharmaceuticals Inc. patent describes new complement C1s subcomponent (C1S) inhibitors potentially useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic ...
In my November 2024 column, I began discussing the building block approach for crashworthiness testing of composite structures. This approach features a multistep process for designing composite ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback